1. bookVolume 28 (2015): Edizione 3 (September 2015)
Dettagli della rivista
Prima pubblicazione
30 May 2014
Frequenza di pubblicazione
4 volte all'anno
Accesso libero

The significance of the adenosinergic system in morphine dependence

Pubblicato online: 26 Nov 2015
Volume & Edizione: Volume 28 (2015) - Edizione 3 (September 2015)
Pagine: 164 - 169
Ricevuto: 29 Jul 2015
Accettato: 19 Aug 2015
Dettagli della rivista
Prima pubblicazione
30 May 2014
Frequenza di pubblicazione
4 volte all'anno

1. Ahlijanian M.K., Takemori A.E.: Changes in adenosine receptor sensitivity in morphine-tolerant and - dependent mice. J. Pharmacol. Exp. Ther., 236, 615-620, 1986.Search in Google Scholar

2. Ahlijanian M.K., Takemori A.E.: Ef fects of /-/-N6-(Rphenylisopropyl)- adenosine (R-PIA) and caffeine on nociception and morphine-induced analgesia, tolerance and dependence in mice. Eur. J. Pharmacol., 112, 171-179, 1985.10.1016/0014-2999(85)90493-5Search in Google Scholar

3. Ahlijanian M.K., Takemori A.E.: The effect of chronic administration of caffeine on morphine-induced analgesia, tolerance and dependence in mice. Eur. J. Pharmacol., 120, 25-32, 1986.10.1016/0014-2999(86)90635-7Search in Google Scholar

4. Al-Hasani R., Bruchas M.R.: Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology, 115(6), 1363-1381, 2011.10.1097/ALN.0b013e318238bba6Search in Google Scholar

5. Allgaier C., Hertting G., Kugelgen O.V.: The adenosine receptormediated inhibition of noradrenaline release possibly involves an N-protein and is increased by alpha 2-autoreceptor blockade. Br. J. Pharmacol., 90(2), 403-412, 1987.10.1111/j.1476-5381.1987.tb08970.xSearch in Google Scholar

6. Barth A. et al.: Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Brain Res., 762, 79-88, 1997.10.1016/S0006-8993(97)00348-XSearch in Google Scholar

7. Belardinelli L., Linden J., Berne R.M.: The cardiac effects of adenosine. Prog. Cardiovasc. Dis., 32, 73-97, 1989.10.1016/0033-0620(89)90015-7Search in Google Scholar

8. Brailowsky S. et al.: Morphine-theophylline interaction: antagonism or facilitation? Br. J. Pharmacol., 73, 887-92, 1981.10.1111/j.1476-5381.1981.tb08742.xSearch in Google Scholar

9. Brundege J.M., Williams J.T.: Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. J. Neurophysiol., 87, 1369-1375, 2002.10.1152/jn.00508.2001Search in Google Scholar

10. Capasso A.: Adenosine receptors are involved in the control of acute naloxone-precipitated withdrawal: in vitro evidence. Life Sci., 66, 873-883, 2000.10.1016/S0024-3205(99)00671-2Search in Google Scholar

11. Carr G.D., Fibiger H.C., Phillips A.G. (1989). Conditioned place preference as a measure of drug reward. In: The neuropharmacological basis of reward. Lieberman J.M., Cooper S.J.(editors). Oxford: Oxford University Press; p. 264-319.Search in Google Scholar

12. Chen J., Van Praag H.M., Gardner E.L.: Activation of 5-HT, receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res., 543, 354-357, 1991.10.1016/0006-8993(91)90050-6Search in Google Scholar

13. Ciruela F. et al.: Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci., 26, 2080-2087, 2006.10.1523/JNEUROSCI.3574-05.2006Search in Google Scholar

14. Collier H.O.J., Francis D.L.: Morphine abstinence is associated with increased brain cyclic AMP. Nature, 255, 159-162, 1975.10.1038/255159b0Search in Google Scholar

15. Coradetti R. et al.: Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur. J. Pharmacol., 104, 19-26, 1984.10.1016/0014-2999(84)90364-9Search in Google Scholar

16. de Mendonca A., Sebastiao A.M., Ribeiro J.A.: Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport, 6, 1097-1100, 1995.10.1097/00001756-199505300-00006Search in Google Scholar

17. De Montis M.G. et al.: Decreased adenosine A2 receptor function in morphine dependent rats. Pharmacol. Res., 25, 232-233, 1992.10.1016/1043-6618(92)90378-OSearch in Google Scholar

18. Dhalla A.K. et al.: Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr. Top. Med. Chem., 3, 369-385, 2003.10.2174/1568026033392246Search in Google Scholar

19. DiChiara G., Imperato A.: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA., 85, 5274-5278, 1988.10.1073/pnas.85.14.5274Search in Google Scholar

20. DiChiara G., Imperato A.: Opposite effects of mu and kappa opiate agonist on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharm. Exp. Ther., 244, 1067-1080, 1988.Search in Google Scholar

21. Dixon D.A. et al.: Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann. Pharmacother., 33(4), 480-488, 1999.10.1345/aph.18215Search in Google Scholar

22. Dubey R.K. et al.: Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: Role of A2B receptors. Circulation, 96, 2656-2666, 1997.10.1161/01.CIR.96.8.2656Search in Google Scholar

23. Ferre S. et al.: Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonists binding sites. Neurosci. Lett., 208, 109-112, 1996.10.1016/0304-3940(96)12577-5Search in Google Scholar

24. Ferre S.: Adenosine - dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology, 133, 107-120, 1997.10.1007/s002130050380Search in Google Scholar

25. Ferre S. et al.: Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA., 88, 7238-7241, 1991.10.1073/pnas.88.16.7238Search in Google Scholar

26. Ferre S., Rubio A., Fuxe K.: Stimulation of adenosine A2 receptors induces catalepsy. Neurosci. Lett., 130, 162-164, 1991.10.1016/0304-3940(91)90387-9Search in Google Scholar

27. Fink J.S. et al.: Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain. Res. Mol. Brain Res., 14, 186-195, 1992.10.1016/0169-328X(92)90173-9Search in Google Scholar

28. Fishman P. et al.: Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J. Cell Physiol., 183, 393-398, 2000.10.1002/(SICI)1097-4652(200006)183:3<393::AID-JCP12>3.0.CO;2-GSearch in Google Scholar

29. Fishman P. et al.: The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp. Cell Res., 269, 230-236, 2001.10.1006/excr.2001.5327Search in Google Scholar

30. Fishman P., Bar-Yehuda S.: Pharmacology and therapeutic applications of A3 receptor subtype. Curr. Top. Med. Chem., 3, 463-469, 2003.10.2174/1568026033392147Search in Google Scholar

31. Fredholm B.B. et al.: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 53, 527-552, 2001.Search in Google Scholar

32. Ho E.L. et al.: Effect of cyclic nucleotides and phosphodiesterase inhibition on morphine tolerance and physical dependence. Life Sci., 16, 1895-1900, 1975.10.1016/0024-3205(75)90298-2Search in Google Scholar

33. Jarvis M.F., Williams M.: Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2 selective agonists, [3H]-CGS 21680. Eur. J. Pharmacol., 168, 243-246, 1989.10.1016/0014-2999(89)90571-2Search in Google Scholar

34. Jin C. et al.: Withdrawal-induced c-Fos expression in the rat centromedial amygdala 24 h following a single morphine exposure. Psychopharmacology, 175, 428-435, 2004.Search in Google Scholar

35. Kaplan G.B., Leite-Morris K.A., Sears M.T.: Alterations in adenosine A1 receptors in morphine dependence. Brain Res., 657, 347-350, 1994.10.1016/0006-8993(94)90990-3Search in Google Scholar

36. Kaplan G.B., Leite-Morris K.A.: Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Res., 763, 215-220, 1997.10.1016/S0006-8993(97)00413-7Search in Google Scholar

37. Kitakaze M., Hori M.: Adenosine therapy: a new approach to chronic heart failure. Expert Opin. Investig. Drugs., 9, 2519-2535, 2000.10.1517/13543784.9.11.2519Search in Google Scholar

38. Koob G.F., Volkow N.D.: Neurocircuitry of addiction. Neuropsychopharmacology, 35, 217-238, 2010.10.1038/npp.2009.110Search in Google Scholar

39. Ledent C. et al.: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature, 388, 674-678, 1997.10.1038/41771Search in Google Scholar

40. Li H., Henry J.L.: Adenosine receptor blockade reveals N-methyl- D-aspartate receptor- and voltage-sensitive dendritic spikes in rat hippocampal CA1 pyramidal cells in vitro. Neuroscience, 100, 21-31, 2000.10.1016/S0306-4522(00)00249-9Search in Google Scholar

41. Linden J.: Molecular approach to adenosine receptors: receptormediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol., 41, 775-787, 2001.10.1146/annurev.pharmtox.41.1.775Search in Google Scholar

42. Listos J., Poleszak E., Malec D.: The influence of adenosine receptor agonists and antagonists on morphine place preference in rats. Annales UMCS, Pharmacia, sectio DDD, 15(1), 185-200, 2002.Search in Google Scholar

43. Listos J., Talarek S., Fidecka S.: Involvement of adenosine receptor agonists on the development of hypersensitivity to acute dose of morphine during morphine withdrawal period. Pharmacol Rep. 60(5), 679-685, 2008.Search in Google Scholar

44. Lopes L.V. et al.: Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition. Neuroscience, 112, 319-329, 2002.10.1016/S0306-4522(02)00080-5Search in Google Scholar

45. Maldonado R.: The neurobiology of addiction. J. Neural. Transm., 66, 1-14, 2003.10.1007/978-3-7091-0541-2_114582800Search in Google Scholar

46. Malec D., Poleszak E.: Cataleptogenic activity of adenosine analogues in rats. Annales UMCS section DDD, 11, 51-63, 1998.Search in Google Scholar

47. Malec D.: Purinergic receptors. Pol. J. Pharmacol., 48, 457-465, 1996.Search in Google Scholar

48. Marchi M. et al.: Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br. J. Pharmacol., 136, 434-440, 2002.10.1038/sj.bjp.0704712157335712023946Search in Google Scholar

49. Matsuda K.: Experimental studies on the effective procedure to inhibit the development of tolerance to and dependence on morphine. Arzneimittelforschung, 20, 1596-1604, 1970.Search in Google Scholar

50. Mayfield R.D, Suzuki F., Zahniser N.R.: Adenosine A2A receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J. Neurochem., 60, 2334-2337, 1993.10.1111/j.1471-4159.1993.tb03526.x8492136Search in Google Scholar

51. Michalska E., Malec D.: Agonists and antagonists of adenosine receptors and morphine withdrawal syndrome in rats. Pol. J. Pharmacol., 45, 1-9, 1993.Search in Google Scholar

52. Miura T. et al.: Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J. Am. Coll. Cardiol., 35, 238-245, 2000.10.1016/S0735-1097(99)00493-3Search in Google Scholar

53. Munro R. et al.: Differential expression of adenosine A2A and A2B receptor subtypes on myeloid U937 and THP-1 cells: Adenosine A2B receptor activation selectively stimulates cAMP formation and inhibition of TNF-α release in THP-1 cells. Drug Dev. Res., 44, 41-47, 1998.10.1002/(SICI)1098-2299(199805)44:1<41::AID-DDR6>3.0.CO;2-PSearch in Google Scholar

54. Noda Y., Nabeshima T.: Opiate physical dependence and N-methyl- D-aspartate receptors. Eur. J. Pharmacol., 500, 121-128, 2004.10.1016/j.ejphar.2004.07.017Search in Google Scholar

55. O’Neill C. et al.: Adenosine A1 receptor mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors. Eur. J. Neurosci., 26, 3421-3428, 2007.10.1111/j.1460-9568.2007.05953.xSearch in Google Scholar

56. Peyot M.L. et al.: Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A2B-purinoreceptor. Circ. Res., 86, 76-85, 2000.10.1161/01.RES.86.1.76Search in Google Scholar

57. Rebola N. et al.: Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron, 57, 121-134, 2008.10.1016/j.neuron.2007.11.023Search in Google Scholar

58. Ribeiro J.A., Sebastiao A.M., de Mendonca A.: Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol., 68, 377-392, 2002. 10.1016/S0301-0082(02)00155-7Search in Google Scholar

59. Robinson T.E, Berridge K.C.: Incentive-sensitization and addiction. Addiction, 96, 103-114, 2001.10.1046/j.1360-0443.2001.9611038.xSearch in Google Scholar

60. Robinson T.E., Berridge K.C.: The incentive sensitization theory of addiction: some current issues. Phil. Trans. R. Soc. B., 363, 3137-3146, 2008.10.1098/rstb.2008.0093Search in Google Scholar

61. Sawynok J.: Topical and peripherially acting analgesics. Pharmacol. Rev., 55, 1-20, 2003.10.1124/pr.55.1.1Search in Google Scholar

62. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J.: Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem., 57, 1062-1067, 1991.10.1111/j.1471-4159.1991.tb08257.xSearch in Google Scholar

63. Sebastiao A.M., Ribeiro J.A.: Adenosine receptors and the central nervous system. Handb. Exp. Pharmacol., 193, 471-534, 2009.10.1007/978-3-540-89615-9_16Search in Google Scholar

64. Shahidi S., Hashemi-Firouzi N.: The effects of a 5-HT7 receptor agonist and antagonist on morphine withdrawal syndrome in mice. Neurosci. Lett., 578, 27-32, 2014.10.1016/j.neulet.2014.06.027Search in Google Scholar

65. Shindou T. et al.: Adenosine A2A receptor enhances GABA (A)-mediated IPSCs in the rat globus pallidus. J. Physiol., 532, 423-434, 2001.10.1111/j.1469-7793.2001.0423f.xSearch in Google Scholar

66. Song Y. et al.: Selective attenuation of isoproterenol-stimulated arrhythmic activity by a partial agonist of adenosine A1 receptor. Circulation, 105, 118-123, 2002.10.1161/hc0102.101392Search in Google Scholar

67. Spanagel R., Weiss F.: The dopamine hypothesis of reward: past and current status. Trends Neurosci., 22, 521-527, 1999.10.1016/S0166-2236(99)01447-2Search in Google Scholar

68. Trescot A.M. et al.: Opioid Pharmacology. Pain Physician., 11, 133-153, 2008.10.36076/ppj.2008/11/S133Search in Google Scholar

69. Van Schaick E.A. et al.: Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-Sulfophenyl) adenosine in diabetic zucker rats: Influence of the disease on the selectively of action. J. Pharmacol. Exp. Ther., 287, 21-30, 1998.Search in Google Scholar

70. Vanderschuren L.J., Kalivas P.W.: Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology, 151(2-3), 99-120, 2000.10.1007/s00213000049310972458Search in Google Scholar

71. Wardas J., Konieczny J., Lorenc-Koci E.: SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse, 41(2), 160-171, 2001.10.1002/syn.107011400182Search in Google Scholar

72. Wilcox C.S. et al.: Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J. Am. Soc. Nephrol., 10, 714-720, 1999.10.1681/ASN.V10471410203354Search in Google Scholar

73. Wolf M.E.: LTP may trigger addiction. Mol. Interv., 3, 248-252, 2003.10.1124/mi.3.5.248Search in Google Scholar

74. Wood P.L. et al.: Inhibition of nigrostriatal release of dopamine in the rat by adenosine receptor agonists: A1 receptor mediation. Neuropharmacology, 28, 21-25, 1989. 10.1016/0028-3908(89)90062-2Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo